GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2023: USD 23.66 M

GuiZhou SanLi Pharmaceutical Co.,Ltd Free Cash Flow is USD 23.66 M for the year ending December 31, 2023, a -5.84% change year over year. Free cash flow is the amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

GuiZhou SanLi Pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2022 was USD 25.12 M, a 23.79% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2021 was USD 20.30 M, a 1,048.05% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2020 was USD 1.77 M, a -88.62% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Free Cash Flow for the year ending December 31, 2019 was USD 15.54 M, a 45.30% change year over year.

Key data

Date	Free Cash Flow	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years